Advanced Targeted Drug Delivery Global Market

3,400.0010,000.00

Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021

Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment

Published April 2016

For sample pages click here

 

Clear
SKU: N/A Category:

Description

Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021

Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment

Published April 2016

For sample pages click here

 

This newly published report is a global industry analysis on the advanced and targeted drug delivery market that KellySciPub forecasts to grow at a 10.4% CAGR to $319 billion by 2021 from $168 billion today. Supported by over 300 tables and figures, this 382 page report is an extensive industry analysis specifically written for C-Suite, VP and Higher executives within the Pharma and Biotech space.

The advanced and targeted drug delivery market is segmented and analysed through to 2021 with corresponding CAGR breakdown by:

  • Technology (Nanoparticles, Polymers (micelles, dendrimers etc), Monoclonal antibodies, Gold nanoparticles-based drug delivery and imaging, Drug eluting stents)
  • Geography (Global, USA, Europe, RoW)
  • Therapeutic Area (Pulmonary, Ocular drug delivery, Ocular nano-based drug delivery implants, Drug Eluting Stents,
  • Sub-Market Analysis (details below)

 

The monoclonal antibody  market is further broken down and presented as the top selling mAbs by company, class and revenue through to 2021 with corresponding CAGR values.  Specific figures are given in relation to Humira, Remicade, Avastin, Rituxan, Soliris, Herceptin, Kadcyla, Perjeta, Lucentis, Xgeva/Prolia, Stelara and Tysarbi.

The global market for nano-based targeted drug delivery is presented by the following sub-markets liposomes, polymers (micelles, dendrimers etc) and gold nano-particles through to 2021 with corresponding CAGR figures.

The global pulmonary drug delivery market is analysed and presented as metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers through 2021 with corresponding CAGR data. This market is also divided into the following geographical regions USA, Europe, RoW, Global through 2021 with corresponding CAGR analysis.

Our PhD analysts identify breakthrough R&D papers and patents and delve into disruptive technical platforms that is revolutionising drug delivery systems. Business, financial and market analysis is performed on all data collated to yield robust figures and forecast through 2021 with CAGR values. Together, our scientific and business team provides you with their in depth knowledge, experience and perspective on the targeted drug delivery landscape.   Stake holder analysis of key players including innovators, developers and commercial partners is performed and an in depth chapter of 170 companies involved is presented.  The analysis includes details of how is breakthrough technology adoption is changing the drug delivery landscape and also how emerging products like hydrogels, PEGylated phospholipid nanocarriers and cyclodextrins are disrupting conventional markets.

 

Key Questions Answered in this Report:

 

  • What are the maximum drug release times reported for various nano-based drug carriers?
  • What regulatory agencies are approving specific nanomedicines?
  • How many liposome-based drugs are available in the market?
  • How many stealth liposomes have been granted market approval?
  • How many PEGylated liposomes are used for targeted drug delivery?
  • Who are the leading players in liposome-based drug formulation?
  • What are stimuli-responsive polymers?
  • Who are the market leaders in polymer-based drugs?
  • What dendrimer-based drugs are the commercially available for targeted delivery?
  • What are the applications of inorganic nanoparticles in targeted drug deliver?
  • Which companies are focusing on inorganic nanoparticles for targeted drug delivery?
  • What are the applications of magnetic nanoparticles in drug delivery, diagnostic and imaging?
  • What is the global market value of nanomedicines?
  • What is the global market for nanomedicines by therapeutic areas?
  • What is the global market for monoclonal antibodies by geography?
  • What are the best-selling mAbs?
  • What is the global market for major targeted delivery systems?

 

About us

KellySciPub is a global market analysis company, based in Dublin, Ireland. Headed by Deirdre Kelly, PhD, the company provides clients with specific market reports that encompass health care niche areas including immunotherapy, cancer biomarkers, transdermal drug delivery, targeted drug delivery, biosimilars and the emerging pharma markets in China and India. All analyses include detailed cutting edge information designed for top tier professionals within the pharma, biotech and healthcare arena. Major clients include Fortune 500 companies, Universities, Government and healthcare organisations. KellySciPub consults with all clients post sale and provides indispensable advice to ensure customer feedback is unparalleled.

Contact:

Dr Deirdre Kelly,

Business Owner,

Kelly Scientific Publications.

Direct Line 00353860776750

Email: deirdre@kellysci.com

Website: www.kellysci.com

 

Table of Contents

1.0       Executive Summary                                                                                       

1.1       Objectives of Report

1.2       Data Sources & Methodology

1.3       Key Findings & Observations

2.0       Drug Delivery

2.1       Introduction

2.1.1    Pharmacokinetics

2.1.2    Bioavailability

2.2       Process of Drug Absorption

2.2.1    Epithelial Cells

2.2.2    Epithelial Cell Junctions

2.2.3    Drug Absorption Routes

2.2.3.1 Passive Diffusion

2.2.3.2 Facilitated Passive Diffusion

2.2.3.3 Active Transport

2.2.3.4 Endocytic Engulfment

2.2.3.5 Efflux Systems

2.3       Physicochemical Properties of Drugs that Influence Absorption

2.3.1    Partition Coefficient

2.3.2    Prodrugs

2.3.3    Drug Ionization

2.3.4    Molecular Weight

2.3.5    Solubility

2.3.6    Stability

2.4       Pharmacokinetic Process

2.4.1    Absorption

2.4.2    Distribution

2.4.3    Metabolism

2.4.3.1 Cytochrome p-450

2.4.3.2 Conjugation

2.4.4    Excretion

2.5       Controlled Release Drug Delivery

2.5.1    Zero-Order Controlled Release

2.5.2    Variable Release

2.6       Pharmacodynamics

2.6.1    Drug-Receptor Interactions

2.6.2    Chemical Interactions

2.6.3    Dose-Response Relationships

2.7       Biotherapeutics

2.7.1    Proteins & Peptides

2.7.2    Nucleic Acids

2.7.2.1 Gene Therapy

2.7.2.2 Antisense Therapy

2.8       Conclusions

3.0       Advanced & Targeted Drug Delivery

3.1       Introduction

3.2       Rate Controlled Drug Release

3.2.1    Diffusion Controlled Release

3.2.1.1 Membrane-Controlled Devices

3.2.1.2 Polymer Matrix diffusion Controlled/ Monolithic Devices

3.2.2    Dissolution Controlled Release

3.2.2.1 Dissolution Controlled Reservoir

3.2.2.2 Dissolution Controlled Matrix

3.2.3    Osmosis Controlled Drug Release

3.2.4    Mechanical Controlled Drug Release

3.2.5    Bioresponsive Controlled Drug Release

4.0       Site Directed Drug-Targeting

4.1       Introduction

4.2       Essential Factors for Effective Drug Targeting

4.2.1    The Drug to be Delivered

4.2.2    The Drug Target

4.2.3    The Drug Delivery System

4.3       Physiological Barriers to Drug Targeting

4.3.1    Elimination of the Drug Carrier

4.3.1.1 Mononuclear Phagocyte System (MPS)

4.3.1.2 Opsonisation

4.3.2    Escape From the Circulation

4.4       Types of Drug Targeting

4.4.1    Passive Drug Targeting

4.4.1.1 Passive targeting by the MPS

4.4.1.2 Local Physiological Conditions

4.4.1.3 Enhanced Permeability and Retention (EPR) Effect

4.4.2    Active Drug Targeting

4.4.2.1 Folate Receptors

4.4.2.2 Transferrin Receptors

4.4.2.3 Antibodies

4.4.2.4 Lectin

4.4.2.5 Physical Targeting

4.5       Subcellular Drug Targeting

4.5.1    Targeting the Plasma Membrane

4.5.2    Membrane Trafficking

4.5.3    Targeting to Intracellular Compartments

4.5.3.1 Early Endosomes

4.5.3.2 Late Endosomes and Lysosomes

4.5.3.3 Endoplasmic Reticulum and Golgi Complex

4.5.4    Targeting the Cytosol

4.5.5    Targeting the Nucleus

4.5.6    Targeting Mitochondria

5.0       Carriers For Drug Targeting

5.1       Options for Drug Targeting

5.2       Modification of the Drug

5.2.1    Site Specific Localization

5.2.2    Site Specific Activation of Prodrugs

5.2.3    Antibody Directed Prodrug Therapy (ADEPT)

5.2.3.1 Gene Directed Prodrug Therapy (GDEPT)

5.2.3.2 Virus Directed Prodrug Therapy (VDEPT)

5.2.3.3 Polymer-Directed Enzyme Prodrug Therapy (PDEPT)

5.2.3.4 Clostridia-Directed Enzyme Prodrug Therapy (CDEPT)

5.3       Soluble Drug Carriers

5.3.1    Antibodies

5.3.1.1 Polyclonal Antibodies

5.3.1.2 Monoclonal Antibodies

5.3.1.3 Immunoconjugates

5.3.1.4 Immunotoxins

5.3.1.5 Bispecific Antibodies

5.3.2    Polymeric Conjugates

5.3.2.1 Polymer Backbone

5.3.2.2 Linker

5.3.2.3 Drug

5.3.2.4 Targeting Polymer-Drug Conjugates

5.3.2.5 Small Cytotoxic Protein Neocarzinostatin (SMANCS)

5.3.3    Protein Drug Carriers

5.3.4    Polysaccharide Drug Carriers

5.4       Particulate Drug Carriers

5.4.1    Principles

5.4.2    Dendrimers

5.4.3    Solid Nanoparticles

5.4.3.1 Solid Lipid Nanoparticles

5.4.3.2 Solid Polymeric Nanoparticles

5.4.3.3 Solid Protein Nanoparticles

5.3.3.4 Inorganic Nanoparticles

5.4.4:   Polymeric Micelles

5.4.5    Micro and Nanoemulsions

5.4.6    Liposomes

5.4.6.1 Conventional Liposomes

5.4.6.2 Long-Circulating Liposomes

5.4.6.3 Immunoliposomes

5.4.6.4 Cationic Liposomes

5.4.7     Microspheres

5.4.8    Poly(alkyl cyanoacrylate) Nanoparticles

5.4.9    Lipoprotein Carriers

5.4.10  Niosomes

5.4.11  TransfersomesTM

6.0       Targeted Drug Delivery in the Treatment of Cancer

6.1       Cancer Facts

6.2       Drug Targeting for Cancer

6.3       Local Drug Delivery Strategies for Cancer Treatment

6.3.1    Injection into the tumour

6.3.2    Antineoplastic Drug Implants into Tumours

6.3.3    OncoGel~PGLA/PEG Copolymer-Based Paclitaxel

6.3.4    Tumour Necrosis Factor Therapy

6.3.5    Direct Introduction of Anti-Cancer Agent into an Organ

6.3.6    Electrochemotherapy

6.3.6.1 Bleomycin

6.3.7    Enhancing Drug Delivery by Modulating Vascular and Interstitial Pressure

6.3.8    Convection Enhanced Drug Delivery and Brain Cancer

6.3.9    Paclimer Microspheres and Cancer

6.3.10  Expansile Nanoparticles

6.3.11  Chitosan Hydrogels

6.3.12  Polymer Millirods

6.3.13  Flexible Film Composites

6.3.14  Lipiodol-Drug Combination

6.3.15  DC Bead

6.3.16  Liposomal Gene therapy.

6.4       Selective Destruction of Cancer Cells

6.4.1    Sphingolipids

6.4.2    Hyperbaric Oxygen (HBO)

6.4.3    Selective Killing of Cancer Cells by Small Molecule Targeting the Stress Response

6.4.4    Targeting Enzymes to Prevent Proliferation of Cancer Cells- Polo-Like Kinase 4 Inhibitor CFI-400945 Fumarate

6.5       Targeted Drug Delivery to Cancer

6.5.1    Affibody Molecules for Targeted Anticancer Therapy

6.5.2    Antibodies for Targeting of Radionuclides in Anticancer Therapy

6.5.3    Targaceutical Technology

6.5.4    PEGylated Liposomes

6.5.5    Genetic Targeting of Kinase Activity in Cancer Cells

6.5.6    Heat-Activated Targeted Drug Delivery

6.5.7    Novel Transporters to Target Photosensitizers to Cancer Cell Nuclei

6.5.8    Photodynamic Therapy of Cancer

6.5.9    Aptocine: A Photodynamic Cancer Vaccine?

6.5.10  Radionuclides Delivered with Receptor Targeting Technology

6.5.11  Transferrin for Drug Targeting to Cancer Cells

6.5.12  Lectins for Drug Targeting to Cancer Cells

6.5.13  Epidermal Growth Factor

6.5.14  Aptamer Mediated Drug Targeting

6.5.15  Tumour Targeting with Peptides

6.5.16  Antibody Based Targeting

6.5.17  Targeting Abnormal DNA in Cancer Cells

6.5.18  Targeted Delivery by Tumour-Activated Prodrug Therapy

6.5.19  Targeting Glutathione S-Transferase

6.5.20  Targeting Tumours by Exploiting Leaky Blood Vessels

6.5.21  Targeted Delivery of Anticancer agents with ReCODE™ Technology

6.5.22  Transmembrane Carrier Systems

6.5.23  Ultrasound and Microbubbles for Targeted Anticancer Drug Delivery

6.5.24  Ultrasound for Targeted Delivery of Chemotherapeutics

6.5.25  Vitamin Based Targeting for Cancer Chemotherapy

6.6       Strategies for Increasing Drug Penetration into Solid Cancers

6.6.1    Improving Drug Transport to Tumors

6.6.1.1 Combination Carbohydrate-Assisted Chemotherapy

6.6.1.2 Dextran Conjugates as Anticancer Drug Carriers

6.6.1.3 In situ Production of Anticancer Agents in Tumors

6.6.1.4 Electrochemotherapy

6.7       Cell-Based Drug Delivery in Cancer

6.7.1    Transduced Cells as Vehicles for Gene Delivery

6.7.2    Macrophages as Vehicles For Drug Delivery

6.7.3    Red Blood Cells as Vehicles For Drug Delivery

6.8       Chronotherapeutic Drug Delivery Systems (ChrDDs)

6.9       Angiogenesis and Drug Delivery to Tumors

6.9.1    Targeting Tumour Endothelial Cells

6.9.2    Vascular Targeting Agents as Cancer Therapeutics

6.9.3    Vascular Targeted Endoradiotherapy of Tumours using Alpha-Particle-Emitting Compounds

6.9.4    Targeted Delivery of Tissue Factor

6.10     Delivery of Proteins and Peptides for Cancer Therapy

6.10.1  CELLECTRA™ for Delivery of Cancer Vaccines

6.10.2  Emisphere’s Eligen™ System

6.10.3  Diatos DTS-201

6.10.4  Cationic Antimicrobial Peptides

6.10.5  Modification of Proteins and Peptides with Polymers

6.10.6  Peptidomimetics in Cancer Targeting

6.10.7  Peptide-Cytokine Complexes as Vascular Targeting Agents

6.10.8  Protein Transduction Technology

6.10.9  Cell Penetrating Peptides (CPPs)

6.11     Targeted Delivery of Nucleic Acids for Cancer Therapy

6.11.1  Viral Vectors for Targeted Nucleic Acid Delivery

6.11.2  Non-Viral Vectors for Targeted nucleic acid Delivery

6.11.2.1            Monoclonal Antibodies

6.11.2.2            Transferrin

6.11.2.3            RGD Peptide

6.11.2.5            Aptamers

6.11.2.4            Folate Receptors

6.11.2.5.1         Aptamer-siRNA Chimeras in Prostate Cancer

6.11.2.6            Polysaccharides

6.11.3  Cell Mediated Targeting

6.11.3.1            Physical Targeting

6.11.3.1.1         Electroporation

6.11.3.1.2         Heat and Irradiation

6.11.3.1.3         Ultrasound

6.11.3.1.4         Magnetic Cell Mediated

6.11.3.1.5         Photochemical Internalization (PCI)

7.0       Targeted Drug Delivery for the Treatment of Infectious Disease

7.1       Tuberculosis

7.1.2    Global Impact of TB

7.1.3    Treatment of TB

7.1.4    TB and HIV

7.1.5    Multidrug-Resistant TB

7.1.6    Targeted Drug Delivery Methods for TB Therapy

7.1.6.1 Inhalable Antitubercular Drugs

7.1.6.2 Inhalable Dry Powder Formulations for TB Treatment

7.1.6.2.1           Liposomal Dry Powder

7.1.6.2.2           Microparticles

7.1.6.2.3           Nanoparticles

7.2       Malaria

7.2.1    Diagnosis and Treatment

7.2.2    Antimalarial Drug Resistance

7.2.3    Pathogenesis of Malarial Infection

7.2.4    Nanotechnology for the Treatment of Malaria

7.2.5    Lipid Based Nanocarriers for Antimalarials and Vaccines

7.2.5.1 Liposomes as Antimalarial Carriers

7.2.5.1.1           Conventional and Long-Circulating Liposomes

7.2.5.1.2           Negatively Charged Liposomes

7.2.5.2             Targeted Liposomes

7.2.5.3             Peptide Targeted Liposomes

7.2.5.4             Antibodies to Target Liposomes

7.2.5.5             Liposomes as Anti-Malarial Vaccine Adjuvants

7.2.5.6             SLNs as Carriers for Anti-Malarials

7.2.5.7             Emulsions as Carriers for Anti-Malarials

7.2.6    Polymers as Nanocarriers for Anti-Malarials

7.2.7    Other Nanocarriers for Anti-Malarials

7.2.7.1             Cyclodextrins and Inclusion Complexes with Anti-Malarials

7.2.7.2             Nanosuspensions as Carriers for Anti-Malarials

7.2.8    Nanocapsules

7.2.9    Drug Delivery to the Malaria Parasite Using an Arterolane-Like Scaffold (195)

7.2.10  Conclusions

7.3       HIV/AIDS

7.3.1    Treatment of HIV/AIDS

7.3.2    Targeting Strategies for the Delivery of Anti-HIV Drugs

7.3.2.1 Targeting the Virus

7.3.2.1.1           Glycoprotein-120

7.3.2.1.2           Glycoprotein-41

7.3.2.2 Targeting the Host Cell

7.3.2.2.1           Leukocyte Function Associated Antigen 1 (LFA-1)

7.3.2.2.2           Human Leukocyte Antigen (HLA)

7.3.2.2.3           C-type Lectin DC-SIGN

7.3.2.2.4           Cell Surface Glycoprotein CD4

7.3.2.2.5           Chemokine Receptor

7.3.2.2.6           Carbohydrate Binding Agents (CBAs)

7.3.2.2.7           Tuftsin

7.3.2.2.8           Transferrin

7.3.2.2.9           Aptamers

7.3.2.2.10         Low-density Lipoprotein (LDL)

7.3.2.3 Passive Targeting

7.3.2.4 Potential Targets

8.0       Targeted Drug Delivery by Physiological Region

8.1       Blood Brain Barrier

8.1.1                The Neurovascular Unit

8.1.2                Transport Across the Blood Brain Barrier

8.1.3                Biological and Pathological Properties of the Blood Brain Barrier for Drug Transport

8.2       Modern Methods for Drug Transport Across the Blood Brain Barrier

8.2.1    Opening Tight Junctions

8.2.2    Transport System Mediated Drug Delivery

8.2.2.1             Nanocarriers for Drug Delivery to the Brain

8.2.2.2             Aggregated Amphiphiles

8.2.2.3             IgG Fusion Proteins

8.2.3    Transport Vectors

8.2.4    Adsorptive Mediated Transcytosis

8.2.5    Receptor Mediated Transcytosis

8.2.6    Inhibition of Efflux Pumps by Pluronic® Block Copolymers

8.2.7    Cell Mediated Drug Transport

8.2.7.1             Microglial Cells

8.2.7.2             Neural Stem Cells

8.2.8    Cell Encapsulation Technology

8.3       Opening the Blood Brain Barrier For Drug Delivery

8.3.1    Osmotic Opening of the BBB

8.3.2    Focal Disruption of BBB by Ultrasound

8.3.3    Chemical Opening of the BBB

8.3.4    Rapid and Reversible Enhancement of BBB Permeability Using Lysophosphatidic Acid

8.3.5    Minimally Invasive Molecular Delivery Into the Brain Using Optical Modulation of Vascular Permeability

8.3.6    Use of Nitric Oxide Donors to Open the BBB

8.3.7    Manipulation of the Sphingosine 1-Phosphate Receptor System

8.3.8    Application of Bradykinin-Analogue (RMP-7, Cereport® from Alkermes)

8.3.9    Transport Across the BBB by Short Chain Oligoglycerolipids

8.3.10  Peptide Masking

8.4.1    G-Technology®

8.4       Pharmacological Strategies to Enhance CNS Drug Delivery

8.4.2    Glycosylation Independent Lysosomal Targeting (GILT)

8.4.3    Chemical Structure Modification and Co-Administration of P-Glycoprotein Inhibitors

8.4.4    LipoBridge Technology

8.4.5    Exosome-Mediated Delivery of siRNA Into the Brain

8.4.6    2 B-Trans™ Technology in Gene Therapy of Alzheimer’s Disease

8.4.7    Roche Brain Shuttle

8.5       Physical Strategies to Enhance CNS Delivery

8.5.1    Intranasal Delivery

8.5.2    Intracranial Drug Delivery

8.5.3    Intracerebroventricular Injection

8.5.4    Intrathecal Administration

8.5.5    Implants for Drug Delivery

8.5.6    Devices for Drug Delivery to the CNS

8.5.7    Convection-Enhanced Delivery (CED) to the CNS

8.5.8    Drug Delivery from Biological Tissues

8.5.9    Intra-Arterial Drug Delivery to the Brain

8.5.10  Direct Injection into the CNS Substance or CNS Lesions

8.5.11  Intraventricular Injection of Drugs

8.5.12  Bacteriophage as CNS Therapeutics

8.5.13  Intrabodies

8.6       Delivering Gene Therapy to the Brain

8.6.1    Introduction

8.6.1.1             Glioblastoma- A Case Study Using Viral Vectors

8.6.1.2             Cytotoxic Gene Therapy

8.6.1.3             Stem cells as Oncolytic Virus Carriers

8.6.1.4             Suicide Gene Prodrugs

8.6.1.5             Immune Stimulation

8.6.1.6             Anti-Angiogenesis Strategies

8.6.1.7             Non- Viral Vectors for Gene Therapy Delivery to the Brain

8.2.1.8             Trojan Horse Liposomes

8.6.2    Targeting Antisense to the Brain

8.6.2.1             Antisense Therapy

8.6.2.2             Trojan Horse Liposomes- Targeting Antisense RNA Gene in Brain Cancer

8.6.2.3             High-Flow Microinfusion into the Brain Parenchyma

8.6.2.4             Introduction of Antisense Compounds into the CSF Pathways

8.6.2.5             Biodistribution of Antisense Compounds Following Intrathecal Administration

8.6.2.6             Intracerebroventricular Administration of Antisense Oligonucleotides

8.6.3                Targeting RNA Interference (RNAi) to the Brain

8.6.3.1             THL Targeting of an RNAi Gene in Brain Cancer

9.0       Drug Delivery for Treatment of Neurological Disorders

9.1       Parkinson’s disease

9.1.1    Targeted Therapies for Parkinson’s Disease

9.1.1.1             Intracerebral Administration of GDNF

9.1.1.2             Liposomes in Parkinson’s Disease

9.1.1.3             Bolaamphiphiles and V-Smart Technology

9.1.1.4             Trojan Horse Liposomes: Targeting a Therapeutic Gene in Parkinson’s Disease

9.1.1.5              Delivery of Cerebral Dopamine Neurotrophic Factor with Microbubbles and Ultrasound

9.1.1.6             Using Exosomes to Deliver siRNA for Synuclein Knockdown

9.1.1.7             Targeted Drug Delivery for Parkinsons’s Disease

9.1.1.8             Cell Therapy for Parkinson’s Disease

9.1.1.8.1           Porcine Xenograft

9.1.1.8.2           Encapsulated Cells

9.1.1.8.3           Stem Cells

9.1.1.8.4           Human Retinal Pigment Epithelium Cells

9.1.1.9              Gene Therapy for Parkinson Disease

9.1.1.10            Convection Enhanced Drug (CED) Delivery in Parkinson’s Disease

9.2       Alzheimer’s Disease

9.2.1    Drug Delivery for Alzheimer’s Disease

9.2.1.1              Perispinal Etanercept (172)

9.2.1.2             Debio 9902 (ZT-1) for Alzheimer´s Disease

9.2.1.3              Brain Derived Neurotrophic Factor (BDNF) for Alzheimer’s Disease

9.2.1.4             Chemical Modification of Disease Therapeutic Peptides

9.2.1.5              Liposomes for Drug Delivery in Alzheimer’s Disease

9.2.1.6              Convection Enhanced Drug (CED) Delivery in Alzheimer’s Disease

9.2.2    Cell and Gene Therapy for Alzheimer Disease

9.2.2.1             Encapsulated Cell Therapy in Alzheimers Disease

9.2.2.2              RNAi therapy of Alzheimer’s Disease

9.3       Huntington’s Disease

9.3.1    Treatment of Huntington’s Disease

9.3.2    Gene therapy of Huntington’s Disease

9.3.2.1             Using Encapsulated Cells to Treat Huntington’s Disease

9.3.2.2              Adeno-Associated Viral Vector Mediated Administration of Neurotrophic Factors

9.3.2.3              Nucleotide Therapeutics for Huntingtin’s Disease Treatment

9.4       Amyotrophic Lateral Sclerosis (ALS)

9.4.1    Treatment of ALS

9.4.2    Gene and Antisense Therapy of ALS

9.4.3.1              Familial ALS

9.4.3.2              Sporadic ALS

9.5       Stroke

9.5.1    Targeted Drug Delivery to Obstructed Blood Vessels Using Nanotherapeutics

9.5.2    Drug Delivery for Prevention of Restenosis of Carotid Arteries

9.5.2.1             Targeted Local Anti-Restenotic Drug Delivery

9.5.2.2             Intraluminal Drug Delivery

9.5.2.2.1           Drug-Eluting Stents (DES)

9.5.2.2.2           Drug-Eluting Balloons (DEBs)

9.5.2.2.3           Porous and Microporous Balloon

9.5.2.3 Gene Therapy to Prevent Restenosis

9.5.2.4 Nanoparticle Drug-Eluting Stents

9.5.2.5 Nanoparticle Gene-Eluting Stents

9.5.3    Stem Cell Transplant to the Brain

9.6       Multiple Sclerosis

9.6.1    Delivery of Methylprednisolone Across the Blood Brain Barrier

9.6.2    Cell therapy for MS

9.6.3    Treatment of MS Through Selective Repression of the Immune System

9.6.4    Nucleic Acid Therapeutics for the Treatment of MS

9.6.4.1             Gene therapy for MS

9.6.4.2             Antisense for MS ~ATL1102

9.7       Epilepsy

9.7.1    Methods of Delivery of Novel Antiepileptic Therapies

9.7.1.1             Nanocarrier Based Drug Delivery for Epilepsy

9.7.1.2             Prodrugs for Epilepsy

9.7.1.3             Targeting Anti-Epilepsy Drugs

9.7.1.4             Nasal Administration of Anti-Epilepsy Drugs

9.7.1.5             Intracerebral administration of Anti-Epilepsy Drugs

9.7.2    Cell Therapy of Epilepsy

9.7.3    Gene Therapy for Epilepsy

9.8       Migraine

9.8.1    Monoclonal Antibodies for the Prevention of Migraine

10.0     Targeted Drug Delivery to the Lung

10.1     Why Target the Lung?

10.2     Targeting Specific Lung Regions

10.3     Particle Size and Deposition

10.3.1              Small Molecules

10.3.1.1            Hydrophobic Small Molecules

10.3.1.2            Hydrophilic Small Molecules

10.3.2  Macromolecules

10.4     Nanoparticles

10.4.1              Delivery of Nanoparticles using Dry Powder Carriers

10.4.2              Delivery of Nanoparticles using Nebulisation

10.5     Targeting by Cell Surface Interactions

10.6     Nanoparticle Based Gene Delivery to Lungs

11.0     Targeted Drug Delivery to the Skin

11.1     Targeting Vaccines to the Skin

11.2     The Skin as an Immune Organ

11.2.1              Langerhans Cells- Epidermal Antigen Presenting Cells

11.2.2              Keratinocytes- Immune Competent Epithelial cells

11.2.3              Dendritic Epidermal T Cells (DETC) γδ T cells -Specialised Resident Epithelial Cells

11.2.4              Epidermotropic T lymphocytes-Circulating T Cells that home to the Epidermis

11.2.5  Melanocytes-Epidermal Pigment Cells With Immune Properties

11.3     Vaccine Delivery to the Skin

11.3.1              Dissolvable Microneedle Array

11.3.2              Electroporation for Administering DNA Vaccines

11.3.3              Microneedles for Transdermal Vaccine Delivery

11.3.4              Needle-Free Delivery of Vaccines

11.4     Applications for Transdermal Vaccination

11.4.1              HIV/AIDS Vaccine

11.4.2              Transdermal DNA Influenza Vaccine

12.0     Targeted Drug Delivery to The Retina

12.1     Structure of the Retina

12.2     Drug Delivery to the Retina

12.2.1              Systemic

12.2.2              Topical

12.2.3              Intravitreal Injection

12.2.3.1            Liposomes

12.2.3.2            Microspheres/Nanospheres

12.2.3.3            Microemulsions and Dendrimers

12.2.3.4            Verisome

12.2.4              Intravitreal Implants

12.2.5              Scleral Drug Delivery

12.2.5.1            Scleral plugs and Implants

12.2.5.2            Subconjunctival Injections

12.2.6              Suprachoroidal Drug Delivery

12.2.6.1            Microcatheter

12.2.6.2            Hollow Microneedles

12.2.7              Encapsulated Cell Technology

12.2.7.1            NT-501

12.2.7.2            NT-503

12.2.8              Sustained Release Refillable Options

12.2.8.1            MicroPump

12.2.8.2            Port Delivery System

12.3     Transporter Mediated Drug Delivery to the Retina

12.3.1  Strategies to Improve Ocular Bioavailability by Transporter Mediated Drug Delivery

13.0     Targeting The Colon

13.1     Achieving Site-Specific Drug Delivery to the Colon

13.1.1  Primary Approaches

13.1.1.1            pH Sensitive Drugs

13.1.1.2            Time Controlled Release Systems (TCRS)

13.1.1.3            Microbially Triggered

13.1.1.4            Prodrug Approach

13.1.2  Novel Approaches

13.1.2.1            Pressure Controlled Drug Delivery

13.1.2.2            Osmotic Controlled Drug Delivery (OROS-CT)

13.1.2.3            Novel Colon Targeted Delivery System (CODES™)

14.0     Global Market for Targeted Drug Delivery

14.1     Global Drug Delivery Market

14.2.    Overview and Analysis

14.3     Advanced Drug Delivery Market by Geography

14.4     USA Drug Delivery Market

14.5     European Drug Delivery Market

14.6     Emerging Drug Delivery Markets

14.7     The Advanced Drug Delivery Landscape

14.8     Advanced Drug Delivery Market by Therapeutic Area

14.9     Cancer

14.10   Infectious Disease

14.11   Blood Brain Barrier Neurological

14.12   Lung

14.13   Skin

14.14   Colon

14.15   Retina

14.16   Advanced Drug Delivery Market By Technology

15.0     Company Business Profiles, Strategic Evaluation & Financial Analysis

15.1     Abbott/Abbvie

15.2     Adare Pharma

15.3     Allergan

15.4     Alza

15.5     American Biosciences

15.6     Amgen

15.7     Astellas/Gilead

15.8     Astra Zeneca

15.9     Auritec pharma

15.10   Avanti Polar Lipids

15.11   Bausch and Lomb

15.12   Bayer

15.13   BBB Therapeutics

15.14   Becton, Dickinson and Company

15.14   Berna Biotech

15.15   Bicycle Therapeutics

15.16   BioDelivery Sciences International

15.16   Biogen

15.17   Boston Scientific

15.18   Bristol-Myers Squibb Company

15.19   BTG plc

15.20   Celsion Corp

15.x     Cytogel Pharma

15.21   D-Pharm Ltd

15.22   Debiopharm

15.x     Debiotech

15.23   Dendritech

15.24   Domantis/GSK

15.25   Eisai

15.x     Eksigent

15.26   Encapsula nanosciences

15.27   Endo International

15.28   Enzon

15.29   f-star

15.x     Flamel Technologies

 

15.30   Galectin Therapeutics

15.31   Genentech Inc.

15.32   Genmab AS

15.33   Genzyme

15.34   Gilead

15.35   GlaxoSmithKline

15.36   Icon Bioscience

15.37   ImmunoGen Inc.

15.38   Inovio Pharmaceuticals Inc.

15.39   Insmed

15.40   Janssen Pharmaceuticals

15.41   King Pharma

15.42   Ligand/Chiva

15.43   Light Sciences Oncology

15.44   Eli Lilly and Co.

15.45   Merck

15.46   Nanocarrier

15.47   Neopharma

15.48   Northern lipids

15:49   Novartis

15.50   Pfizer

15.51   PharmAthene

15.52   Phosphorex

15.53   pSivida corp

15.54   Purdue

15.55   Roche

15.56   RP Scherer Int /BTG

15.57   Salix Pharma

15.58   Samyang biopharm

15.59   sigma-tau

15.60   Skyepharm ENDO

15.61   Spectrum Pharmaceuticals Inc.

15.62   Spectrum/Talon

15.63   Spherotech

15.64   Surmodics

15.65   Takeda

15.66   Terumo

15.67   TTY Biopharma

15.68   United Therapeutics

15.69   Zeneus (TEVA)

15.70   Zimmer Biomet

16.0     Current Targeted Drug Delivery Products on the Market

17.0     In-Depth SWOT Analysis of the Targeted Drug Delivery Market

17.1     Drivers of the Market

17.1.1  Will Patent Expirations and Introduction of New Technologies Drive the Short Term Market?

17.1.2 Increased Patient Compliance Rates

17.1.3 Increased Incidence of Chronic Conditions and Prevalence Rates

17.1.4 Increased Drug Administration Requirements

17.2     Restraints and Weaknesses of the Advanced and Targeted Drug Delivery Market

17.2.1  Technical Restraints

17.2.2  Drug Adverse Reactions

17.2.3  Drug Failures

17.3      Opportunities Within the Market Place

17.3.1  High Number of Pharmaco & Drug Delivery Company Collaboration

17.4     Challenges and Barriers to Market Entry

18.0     Future Developments and Outlook

Appendix 1: Further Reading & Bibliography                                                           

 

You may also like…